Literature DB >> 28348268

Cutting Edge: Class II-like Structural Features and Strong Receptor Binding of the Nonclassical HLA-G2 Isoform Homodimer.

Kimiko Kuroki1, Kazuhiro Mio2, Ami Takahashi1, Haruki Matsubara1, Yoshiyuki Kasai1, Sachie Manaka2, Masahide Kikkawa3, Daizo Hamada4,5, Chikara Sato6, Katsumi Maenaka7.   

Abstract

HLA-G is a natural tolerogenic molecule and has the following unique features: seven isoforms (HLA-G1 to HLA-G7), formation of disulfide-linked homodimers, and β2-microglobulin (β2m)-free forms. Interestingly, individuals null for the major isoform, HLA-G1, are healthy and expressed the α2 domain-deleted isoform, HLA-G2, which presumably compensates for HLA-G1 function. However, the molecular characteristics of HLA-G2 are largely unknown. In this study, we unexpectedly found that HLA-G2 naturally forms a β2m-free and nondisulfide-linked homodimer, which is in contrast to the disulfide-bonded β2m-associated HLA-G1 homodimer. Furthermore, single-particle analysis, using electron microscopy, revealed that the overall structure and domain organization of the HLA-G2 homodimer resemble those of the HLA class II heterodimer. The HLA-G2 homodimer binds to leukocyte Ig-like receptor B2 with slow dissociation and a significant avidity effect. These findings provide novel insights into leukocyte Ig-like receptor B2-mediated immune regulation by the HLA-G2 isoform, as well as the gene evolution of HLA classes.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28348268     DOI: 10.4049/jimmunol.1601296

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients.

Authors:  Diana Tronik-Le Roux; Julie Renard; Jérôme Vérine; Victor Renault; Emmanuel Tubacher; Joel LeMaoult; Nathalie Rouas-Freiss; Jean-François Deleuze; François Desgrandschamps; Edgardo D Carosella
Journal:  Mol Oncol       Date:  2017-09-13       Impact factor: 6.603

2.  Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G Isoforms.

Authors:  Atsushi Furukawa; Manami Meguro; Rika Yamazaki; Hiroshi Watanabe; Ami Takahashi; Kimiko Kuroki; Katsumi Maenaka
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 3.  HLA-G and humanized mouse models as a novel therapeutic approach in transplantation.

Authors:  Ashwin Ajith; Vera Portik-Dobos; Daniel D Horuzsko; Rajan Kapoor; Laura L Mulloy; Anatolij Horuzsko
Journal:  Hum Immunol       Date:  2020-02-21       Impact factor: 2.850

4.  Structural Modeling and Molecular Dynamics of the Immune Checkpoint Molecule HLA-G.

Authors:  Thais Arns; Dinler A Antunes; Jayvee R Abella; Maurício M Rigo; Lydia E Kavraki; Silvana Giuliatti; Eduardo A Donadi
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

Review 5.  The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Authors:  Jiji V D Attia; Charlotte E Dessens; Ricky van de Water; Ruben D Houvast; Peter J K Kuppen; Daniëlle Krijgsman
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 6.  HLA-G Neo-Expression on Tumors.

Authors:  Maria Loustau; François Anna; Raphaelle Dréan; Martin Lecomte; Pierre Langlade-Demoyen; Julien Caumartin
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.